Dr. Landen is an Associate Professor in Gynecologic Oncology, with joint appointments in the Departments of Cancer Biology and Pathology at the University of Alabama at Birmingham. He completed his fellowship in gynecologic oncology at the University of Texas MD Anderson Cancer Center. He is a member of the CDMRP/Department of Defense Ovarian Cancer Academy and a graduate of the Reproductive Scholar Development Program, dividing his time between clinical care and basic/translational research in ovarian cancer. He is a prior recipient the Foundation/Carol’s Cause Outstanding Paper Award and the Foundation/Sarah Biedenhard Ovarian Cancer Research Grant. He is a full member of the Society of Gynecologic Oncology and the American Association for Cancer Research, and serves on the Board of Directors for the Women’s Cancer Foundation and the Norma Livingston Foundation.
Visit the Sisterhood of Survivorship page to read “Dena’s Story” — by a vulvar cancer survivor who has shared her story and wise words, and channeled her energy into her National Race to End Women’s Cancer team.
Vaccine efficacy against vulvar infection with HPV 16/18 was comparable to the efficacy found against cervical infection 4 years after vaccination, according to researchers with the National Cancer Institute.
The Foundation has published its 2014-2015 Research Grants and Awards Booklet with Applications. Please consider applying to become part of an elite group of physician-scientists committed to the well-being of women at risk for/affected by gyn malignancies.